Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?

Ramfidis VS, Strimpakos AS, Syrigos KN, Saif MW.

JOP. 2012 Jul 10;13(4):358-60. doi: 10.6092/1590-8577/948.

3.

Second-line treatment for pancreatic cancer.

Kaddis N, Saif MW.

JOP. 2014 Jul 28;15(4):344-7. doi: 10.6092/1590-8577/2691.

4.

What options are available for refractory pancreatic cancer?

Choi M, Kim R, Saif MW.

JOP. 2012 Mar 10;13(2):163-5. Review.

6.

Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.

Custodio A, Puente J, Sastre J, Díaz-Rubio E.

Cancer Treat Rev. 2009 Dec;35(8):676-84. doi: 10.1016/j.ctrv.2009.08.012. Epub 2009 Sep 15. Review.

PMID:
19758760
7.

First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.

Ramfidis VS, Psyrri A, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):286-8. doi: 10.6092/1590-8577/2622.

8.

First-line treatment for advanced pancreatic cancer.

Kothari N, Saif MW, Kim R.

JOP. 2013 Mar 10;14(2):129-32. doi: 10.6092/1590-8577/1477. Review.

9.

New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.

Ramfidis VS, Syrigos KN, Saif MW.

JOP. 2013 Jul 10;14(4):344-6. doi: 10.6092/1590-8577/1650.

10.

Options for the treatment of gemcitabine-resistant advanced pancreatic cancer.

Gounaris I, Zaki K, Corrie P.

JOP. 2010 Mar 5;11(2):113-23. Review.

11.

Pancreatic cancer: an update.

Kindler HL.

Curr Oncol Rep. 2007 May;9(3):170-6. Review.

PMID:
17430687
12.

Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.

Cartwright T, Richards DA, Boehm KA.

Cancer Control. 2008 Oct;15(4):308-13. Review.

13.

Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.

Gibson TB, Grothey E, Chu E.

Clin Colorectal Cancer. 2008 Jul;7(4):233-9. No abstract available.

PMID:
18650191
14.

Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?

Mayer RJ.

J Clin Oncol. 2007 Sep 20;25(27):4165-7. Epub 2007 Aug 20. No abstract available.

15.

Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer.

Teitelbaum UR, Haller DG.

Nat Rev Clin Oncol. 2009 May;6(5):250-1. doi: 10.1038/nrclinonc.2009.46.

PMID:
19390547
16.

Treatment of colorectal cancer metastasis: the role of chemotherapy.

Xiong HQ, Ajani JA.

Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):145-63. Review.

PMID:
15000155
18.

Pancreatic cancer: will incremental advances begin to make a difference?

Holzman DC.

J Natl Cancer Inst. 2010 Dec 15;102(24):1821-3. doi: 10.1093/jnci/djq521. Epub 2010 Dec 7. No abstract available.

19.

Second-line therapy in pancreatic cancer.

Skoura E, Syrigos KN, Saif MW.

JOP. 2013 Mar 10;14(2):133-4. doi: 10.6092/1590-8577/1463. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk